Neuronetics, Inc. announced a commercial partnership with Alleviant Health Centers. Under the partnership agreement, Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment to Alleviant and its clinics, with an initial six NeuroStar Advanced Therapy systems delivered in 2022. NeuroStar Advanced Therapy is a non-invasive, non-drug treatment that uses transcranial magnetic stimulation to target key areas of the brain that are underactive in people with major depressive disorder (MDD).

NeuroStar is the leading TMS treatment for depression in adult patients and has been proven to be safe and effective, with over 4.5 million treatments delivered to over 127,000 patients to-date.